Brainsway shares rise after FDA clears depression treatment device

Brainsway

29/08/2022 13:50

** U.S.-listed shares of Brainsway  BWAY.O  up $5.4
premarket after FDA clears co's depression treatment device
    ** Braintech co receives FDA clearance for its Deep TMS H7
Coil helmet for use in treating major depressive disorder, and
anxious depression in adults  urn:newsml:reuters.com:*:nGNX5bY5WQ
    ** Co says Deep TMS H7 Coil, which was cleared to treat
obsessive-compulsive disorder in 2018, can now be used against
depression, with no need for an upgrade 
    ** More than 1 mln shares changed hands, more than 60 times
the stock's 50-day moving average volume
    ** Up to last close, stock fell 41.6% YTD

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((Nandhini.srinivasan@thomsonreuters.com))